NASDAQ:PPD PPD (PPD) Stock Price, News & Analysis → #1 election stock (From Porter & Company) (Ad) Free PPD Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$47.28▼$47.2850-Day Range$47.10▼$47.4152-Week Range$31.54▼$47.41VolumeN/AAverage Volume1.91 million shsMarket Capitalization$16.61 billionP/E Ratio47.28Dividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get PPD alerts: Email Address Ad Porter & CompanyThe biggest energy story ever? Discover why I’m calling this one of the biggest developments in the global energy market since the shale revolution… why everything you’ve ever been told about Trump’s environmental record is a lie…For the full story, click here. About PPD Stock (NASDAQ:PPD)PPD, Inc., together with its subsidiaries, provides drug development services to the biopharmaceutical industry worldwide. The company operates through two segments, Clinical Development Services and Laboratory Services. It offers clinical development services, including product development and consulting, early development, Phases II-IV clinical trial management, accelerated enrollment, peri-and post-approval, and medical communications services. The company also provides laboratory services comprising bioanalytical, biomarker, vaccine science, good manufacturing practice, and central laboratory services. It serves pharmaceutical, biotechnology, medical device, and government organizations, as well as other industry participants. The company has a collaboration with Science 37 to design, build, test, implement, and execute digital trials using Science 37's DCT SaaS-based technology platform. PPD, Inc. was founded in 1985 and is headquartered in Wilmington, North Carolina.Read More Ad Porter & CompanyThe biggest energy story ever? Discover why I’m calling this one of the biggest developments in the global energy market since the shale revolution… why everything you’ve ever been told about Trump’s environmental record is a lie…For the full story, click here. PPD Stock News HeadlinesMay 1, 2024 | msn.comMan wounded in broad daylight shooting in PortsmouthMay 1, 2024 | msn.comGunfire incident reported in Peoria neighborhood hours after teen's fatal shootingMay 1, 2024 | True Market Insiders (Ad)The “Next Bitcoin”? 10 CENT Crypto Set to ExplodeThe man who bought Bitcoin and Ethereum in 2017… and has spotted 44 different coins that have returned over 100%... Is now exposing a 10-cent coin that just partnered with Amazon…May 1, 2024 | msn.comPPD searching for missing, endangered man Alexander CookMay 1, 2024 | msn.comVermont H.S. scores, postponements for Tuesday, April 30: See how your favorite team faredApril 30, 2024 | msn.comUsing basketball to improve police-community relations and lower gun violenceApril 30, 2024 | msn.comDriver Robbed Of $40K While Fixing Flat Tire In Philadelphia: AuthoritiesApril 30, 2024 | seekingalpha.comThermo Fisher: Renewed Growth Yet To Materialize, But Already Priced In (Rating Downgrade)May 1, 2024 | True Market Insiders (Ad)The “Next Bitcoin”? 10 CENT Crypto Set to ExplodeThe man who bought Bitcoin and Ethereum in 2017… and has spotted 44 different coins that have returned over 100%... Is now exposing a 10-cent coin that just partnered with Amazon…April 29, 2024 | msn.comMore than 12 pounds of drugs seized, Palestine man arrestedApril 29, 2024 | msn.comPhilly officer reinstated 18 months after judge drops murder charges against himApril 28, 2024 | msn.comPortsmouth police chief condemns deadly shooting of 10-year-old boyApril 28, 2024 | msn.comFamily to hold vigil for 10-year-old killed in PortsmouthApril 28, 2024 | msn.comWeekend violence leaves 4 injured across PhiladelphiaApril 28, 2024 | msn.comHit-and-run in Philadelphia leaves man hospitalized with serious injuries, police sayApril 27, 2024 | msn.comPPD: Boy shot to death on Farragut StreetApril 27, 2024 | msn.comPortsmouth police chief condemns deadly shooting of young boyApril 27, 2024 | msn.comPhoenix police internal investigations 'not thorough' enough, watchdog reports showApril 26, 2024 | markets.businessinsider.comSAGE Therapeutics: Hold Rating Amidst Zurzuvae Success and Dalzanemdor SetbacksApril 26, 2024 | msn.comDetails Emerge In PPD Shooting Of Maurice SamuelsApril 26, 2024 | msn.comPhiladelphia Police Officer Return to PPD After Dismissed Murder ChargesApril 26, 2024 | msn.comBrave four-year-old awarded 911 Hero AwardApril 26, 2024 | msn.comUPDATE: Val U Stay closed by city due to living conditionsApril 26, 2024 | msn.comPacifica police look for person of interest in arson investigationApril 26, 2024 | yahoo.comPPD: Help identify people in video near crime sceneApril 24, 2024 | pnj.comPensacola police warns of phone scams after resident taken for nearly $50,000April 24, 2024 | msn.comDog Attack Leads to Officer-Involved Shooting in West Oak LaneSee More Headlines Receive PPD Stock News and Ratings via Email Sign-up to receive the latest news and ratings for PPD and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings10/27/2021Today5/01/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Commercial Physical Research Sub-IndustryN/A Current SymbolNASDAQ:PPD CUSIPN/A CIK1793294 Webwww.ppdi.com Phone910-251-0081FaxN/AEmployees26,000Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)$1.00 Trailing P/E Ratio47.28 Forward P/E Ratio32.16 P/E Growth2.11Net Income$153.69 million Net Margins6.11% Pretax Margin7.31% Return on Equity-89.48% Return on Assets7.94% Debt Debt-to-Equity RatioN/A Current Ratio1.23 Quick Ratio1.23 Sales & Book Value Annual Sales$4.68 billion Price / Sales3.55 Cash Flow$1.99 per share Price / Cash Flow23.71 Book Value($1.21) per share Price / Book-39.07Miscellaneous Outstanding Shares351,395,000Free Float344,718,000Market Cap$16.61 billion OptionableNot Optionable Beta1.96 10 Best Cheap Stocks to Buy NowMarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesMr. David S. Simmons (Age 56)Chairman & CEO Comp: $3.42MMr. Christopher G. Scully (Age 50)Exec. VP, CFO, Treasurer & Assistant Sec. Comp: $1MMr. William J. Sharbaugh (Age 58)Chief Operating Officer Comp: $1.12MMr. Anshul Thakral (Age 43)Exec. VP, Chief Commercial Officer & Pres of Evidera Comp: $1.13MDr. David Michael Johnston (Age 52)Exec. VP of Global Clinical Devel. Comp: $788.87kMr. Glen Donovan (Age 47)Chief Accounting Officer Mr. B. Judd Hartman (Age 57)Exec. VP & Chief Admin. Officer Ms. Tracy H. Krumme (Age 53)VP & Head of Investor Relations Ms. Julia James (Age 46)Exec. VP, Gen. Counsel & Sec. Mr. Ronald E. Garrow (Age 57)Exec. VP & Chief HR Officer More ExecutivesKey CompetitorsMedpaceNASDAQ:MEDPCharles River Laboratories InternationalNYSE:CRLIncyteNASDAQ:INCYPRA Health SciencesNASDAQ:PRAHICON PublicNASDAQ:ICLRView All Competitors Should I Buy PPD Stock? PPD Pros and Cons Explained Pros Here are some ways that investors could benefit from investing in PPD, Inc.: PPD, Inc. has a strong presence in the biopharmaceutical industry worldwide, offering a wide range of drug development services. David Johnston, Ph.D., the executive vice president and global head of clinical development services at PPD, brings extensive experience and expertise to the company. PPD's Accelerated Enrollment Solutions (AES) business provides data-driven patient recruitment for clinical trials, enhancing efficiency and speed in trial execution. Recent collaborations and partnerships, such as the one with Science 37 for digital trials, demonstrate PPD's commitment to innovation and staying at the forefront of industry trends. Considering the current stock price and market trends, PPD, Inc. shows potential for growth and value appreciation. Cons Investors should be bearish about investing in PPD, Inc. for these reasons: Market volatility and regulatory challenges in the biopharmaceutical industry can impact PPD's operations and financial performance. Dependency on external factors such as government regulations, clinical trial outcomes, and industry competition may pose risks to investment returns. Fluctuations in global economic conditions and healthcare spending could affect the demand for PPD's services and solutions. Uncertainties related to the success of new drug developments and clinical trials could influence the company's revenue streams and profitability. Investors need to carefully assess the competitive landscape and potential threats to PPD's market position to make informed investment decisions. These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Friday, April 12, 2024. Please send any questions or comments about these PPD pros and cons to contact@marketbeat.com. PPD Stock Analysis - Frequently Asked Questions How were PPD's earnings last quarter? PPD, Inc. (NASDAQ:PPD) posted its quarterly earnings results on Wednesday, October, 27th. The company reported $0.43 EPS for the quarter, beating the consensus estimate of $0.38 by $0.05. The business had revenue of $1.56 billion for the quarter, compared to analysts' expectations of $1.41 billion. PPD had a net margin of 6.11% and a negative trailing twelve-month return on equity of 89.48%. PPD's revenue was up 26.5% on a year-over-year basis. During the same period in the previous year, the company posted $0.15 EPS. What other stocks do shareholders of PPD own? Based on aggregate information from My MarketBeat watchlists, some companies that other PPD investors own include Cisco Systems (CSCO), Alibaba Group (BABA), Johnson & Johnson (JNJ), Salesforce (CRM), Pfizer (PFE), CVS Health (CVS), Intel (INTC), NVIDIA (NVDA), RTX (RTX) and Verizon Communications (VZ). When did PPD IPO? PPD (PPD) raised $1.5 billion in an initial public offering (IPO) on Thursday, February 6th 2020. The company issued 60,000,000 shares at $24.00-$27.00 per share. Barclays, J.P. Morgan, Morgan Stanley, Goldman Sachs, BofA Securities, Credit Suisse, Jefferies, UBS Investment Bank, Citigroup, Deutsche Bank Securities, Evercore ISI, HSBC, Mizuho Securities, Baird and William Blair acted as the underwriters for the IPO and BofA Securities, Credit Suisse, Jefferies, UBS Investment Bank, Citigroup, Deutsche Bank Securities, Evercore ISI, HSBC, Mizuho Securities, Baird, William Blair and Drexel Hamilton were co-managers. This page (NASDAQ:PPD) was last updated on 5/1/2024 by MarketBeat.com Staff From Our PartnersHave You Seen Elon’s New A.I. Device? (Picture Inside)InvestorPlace😱 This phenomenon is smashing regular market gainsMillPubDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsPOTUS in ‘25 Not Biden/Trump, ButThe Freeport SocietyAI “wealth window” is closing June 25thParadigm PressForget AI, Imperium Is Expected to Grow 320,00% in 3 YearsBanyan Hill PublishingA.I. is a Tidal Wave - Here’s What to BuyChaikin AnalyticsTrump just won 2024Porter & Company Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding PPD, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
